Background: It is unclear if all patients with relapsing-remitting multiple sclerosis (RRMS) ultimately develop progressive MS. Onset of progressive disease course seems to be age-rather than disease duration-dependent. Some forms of progressive MS (e.g. primary progressive MS (PPMS)) are uncommon in population-based studies. Ascertainment of patients with PPMS from clinic-based populations can facilitate a powerful comparison of age at progression onset between secondary progressive MS (SPMS) and PPMS but may introduce unclear biases. Objective: Our aim is to confirm that onset of progressive disease course is more relevant to the patient's age than the presence or duration of a pre-progression relapsing disease course in MS. Methods: We studied a population-based MS cohort (n=210, RRMS n=109, progressive MS n=101) and a clinic-based progressive MS cohort (n=754). Progressive course was classified as primary (PPMS; n=322), single attack (SAPMS; n=112) and secondary progressive (SPMS; n=421). We studied demographics (chi 2 or t-test), age-of-progression-onset (t-test) and time to Expanded Disability Status Scale of 6 (EDSS6) (Kaplan-Meier analyses). Results: Sex ratio (p=0.58), age at progression onset (p=0.37) and time to EDSS6 (p=0.16) did not differ between the cohorts. Progression had developed before age 75 in 99% of patients with known progressive disease course; 38% with RRMS did not develop progression by age 75. Age at progression onset did not differ between SPMS (44.9±9.6), SAPMS (45.5±9.6) and PPMS (45.7±10.8). In either cohort, only 2% of patients had reached EDSS6 before onset of progression. Conclusions: Patients with RRMS do not inevitably develop a progressive disease course. Onset of progression is more dependent on age than the presence or duration of a pre-progression symptomatic disease course. Moderate disability is sustained predominantly after the onset of a progressive disease course in MS.
Introduction
The course of multiple sclerosis (MS) is classified based on the temporal relationship between relapses from which patients typically experience partial or complete recovery and progression of irreversible central nervous system dysfunction. 1-4 A purely relapsing-remitting disease course (RRMS) is characterized by the absence of worsening neurological function outside of individual relapses. In this study, we focus on the onset of the progressive disease course in MS defined by the onset of insidiously worsening and irreversible neurological function, regardless of absence or presence of preceding relapses and that cannot be explained purely by a stepwise worsening associated with ongoing relapses.
A progressive disease course may start without preceding relapses (primary progressive MS (PPMS)) or follow symptomatic relapses (bout-onset progressive MS (BOPMS)). In the BOPMS groups, single attack progressive MS (SAPMS) refers to progression following a clinically isolated syndrome (CIS), and secondary progressive MS (SPMS) refers to progression following RRMS. 5 We seek to confirm that the onset of progressive MS may be more relevant to the patient's age than the duration of a pre-progression relapsing disease course. 2, [5] [6] [7] [8] We hypothesize that the presence (BOPMS) or absence (PPMS) of a symptomatic relapsing-remitting period preceding onset of progressive disease course in MS may have no impact on age at onset of progression. We ask the specific question: is age at progression onset similar in the sub-groups of SPMS, SAPMS and PPMS? We also address several additional challenges that can confound the ascertainment and comparison of age at progression onset in the sub-groups of SPMS, SAPMS and PPMS.
Population-based studies are the standard for determining age-related milestones, but may have limited power to study relatively uncommon forms of progressive MS (e.g. PPMS). Patients with progressive MS are commonly referred to tertiary care clinics due to challenges associated with their care, enriching clinic-based populations for the uncommon forms of progressive MS. However, mostly retrospective determination of age at progression onset in clinic-based cohorts is likely more prone to recall bias than in prospectively followed population-based cohorts. Men have an older age at progression onset and more severe MS than women. 1,9 Therefore, potential referral of more severe cases and potentially more men to clinicbased cohorts could lead to earlier estimates of age at progression onset than in population-based studies. To address the potential impact of recall and referral biases on age at progression onset, we uniquely compare a clinicbased cohort of patients with MS with a population-based cohort of MS patients ascertained in the same clinical practice for the sex ratio, age at progression onset and the time-to-moderate-disability milestone of Expanded Disability Status Scale of six (EDSS6). 5, 10 Some patients with CIS or RRMS are not followed long enough to develop progressive disease course. The resulting censoring needs to be considered in studies focusing on age at progression onset in BOPMS. 6 This provides a challenge when comparing BOPMS patients with PPMS. By definition, all patients with PPMS have already reached the age milestone at the time of diagnosis. If some patients with CIS or RRMS will never develop progression, inclusion of these patients in longitudinal studies may lead to older estimates of age at progression onset for the BOPMS group than the PPMS group. In this study, we also seek to find out whether all patients with RRMS develop progressive MS in a longitudinally followed population-based cohort.
Methods

Study populations
All patients were seen and followed at the Mayo Clinic Center for MS and CNS Demyelinating Diseases, a tertiary care provider for complicated referral patients with MS and a primary care provider for regional patients with MS.
We studied two cohorts fulfilling McDonald diagnostic criteria for MS: 11, 12 a population-based MS cohort from Olmsted County, MN, USA, established in 1992 13 and reascertained in 2002 (n=221, age ≥18 years), 14, 15 and a clinic-based progressive MS cohort (n=859, age ≥18 years) established from patients seen from 2003 through 2007, with observed progression of at least 1 year ( Figure 1 ).
Definition of progression
We defined progression as insidious and irreversible worsening brain, brainstem-cerebellar and spinal cord syndromes most commonly characterized by progressive weakness, ataxia or bladder dysfunction of ≥1 year. We did not include patients with exclusive sensory progression due to subjectivity and variability in recording change in intensity of sensory symptoms. Typical of a standard clinical practice setting, the most detailed and rigorous historical documentation and clinical examination closest in time to progression onset was used to establish the date of onset of progression.
Disease course classification
PPMS is defined as progression without previous relapses. SAPMS is defined as progression following a CIS. 5 SPMS is defined as progression following RRMS. Although separated for understanding potential impact of a single critical relapse before progression onset, SAPMS and SPMS are also grouped together as BOPMS when appropriate for the analyses.
Rather than as a separate relapsing-progressive MS category, ongoing relapses after onset of progression were considered as part of a continuum of the symptomatic (BOPMS) or subclinical (PPMS) relapsing phase as it evolved into progressive phase of MS.
The population-based cohort captured RRMS patients with or without conversion to SPMS despite a ≥20-year follow-up. As a tertiary care referral practice, the clinicbased cohort captured a population enriched for less common forms of progressive MS (PPMS and SAPMS) than SPMS.
Study variables and outcomes
We extracted the following variables: sex; age at MS onset; age at progression onset; year of progression onset; age at sustained disability of the clinically well-recognized and well-recorded milestone of EDSS6 5, 10 or needing a cane to walk; age at last relapse; occurrence of pre-progression and post-progression relapses. We studied the following outcomes: time from onset of MS to onset of progression, age at progression onset, and time from progression onset to EDSS6 (time to EDSS6).
Data extraction and validation
In the population-based cohort with prospective follow-ups in our center, two neurologists with subspecialty training in MS (JT, MT) independently reviewed all neurologic and non-neurologic records and agreed on date of progression and date of EDSS6 in each case.
Two additional neurologists with MS subspecialty training (NA, NK) reviewed all neurologic and non-neurologic records for the clinic-based cohort. Year of progression onset was identical according to the two reviewers in 26 of the first 30 reviewed patients. The year of attaining EDSS6 matched in 26 of 28 patients (two of 30 had not reached EDSS6 in this group). In the cases where records at different time points indicated different dates for progression onset or EDSS6, decision was made to use the earliest record closest to the event date. Any final discrepancies were arbitrated by the principal investigator (OK). Despite consensus that the course was progressive, we could not clarify presence or absence of pre-progression relapses in † 'Progression' refers to insidious and irreversible worsening brain, brainstem-cerebellar and spinal cord syndromes most commonly characterized by progressive weakness, ataxia or bladder dysfunction of ≥1 year ‡ The term 'No progression' refers to patients whose disability derives from incomplete recovery from ongoing relapses alone rather than from insidious accumulation of neurological deficits.
19 (2.5%) patients from the clinic-based cohort, who were excluded from the final analyses ( Figure 1 ).
Data analyses
To assess for potential impact of referral and recall biases on age at progression onset in the largely retrospective tertiary care clinic population, we compared sex ratio, age at MS onset, age at progression onset and time to EDSS6 in the two cohorts. Demographic and clinical features in different models were compared by Chi 2 or t-tests as appropriate. Kaplan-Meier analysis was used to account for censoring, age-or time-scaled outcomes (i.e. where RRMS patients that are yet-to-progress are included in the analyses). Mean values with standard deviations from the mean were provided when appropriate (i.e. where all patients included in the analyses have reached the outcome).
Results
To prevent double-counting of patients in the final analyses, patients who overlapped the two cohorts were included in the population-based cohort (Figure 1 ). Analyses were performed with 109 patients who still had RRMS without clinical progression (mean follow-up ± SD: 22.4 ± 11.9 years; 71% ≥15 and 40% ≥25 years follow-up), 101 patients with progressive MS (80 SPMS, 6 SAPMS, 15 PPMS) from the population-based cohort and 754 patients with progressive MS (341 SPMS, 106 SAPMS, 307 PPMS) from the clinic-based cohort (Figure 1 ).
To account for regional patient-referral patterns that could impact age at progression onset, the clinic-based cohort was further sub-grouped to include only the patients from the states within latitudes 40-50° surrounding Olmsted County (MN, ND, SD, NE, WI, IA, MI -upper peninsula) (Table 1) . There was no difference in regional versus non-regional referrals in any of the outcomes that were analyzed; therefore they were grouped for further analyses. Table 1 shows the demographic aspects of patients with progressive MS from the population-based cohort compared with the clinic-based cohort. Analyses were done both by including and excluding PPMS patients. Sex ratio did not differ between populations (Table 1) .
Do sex ratio, age at progression onset and time to EDSS6 differ between clinic-based and population-based MS patients?
MS onset was 3.5 years older for patients with BOPMS in the clinic-based cohort compared with the populationbased cohort (mean ± SD: 33.5 ± 9.6 years vs. 29.9 ± 8.8 years; p=0.001) (Table 1) . Age at progression onset (p=0.37) did not differ between clinic-and population-based cohorts (Table 1) . Time to EDSS6 did not differ between clinic-and population-based cohorts, regardless of inclusion (p=0. 16) or exclusion (p=0.86) of PPMS ( Figure 2 ).
Despite a long follow-up (mean ± SD: 22.8 ± 11.8 years), only two of 109 (1.8%) patients in the RRMS group without secondary progression reached EDSS6. Similarly, two of 85 (2.4%) patients from the population-based cohort and seven of 447 (1.6%) patients from the clinic-based cohort with established BOPMS reached EDSS6 before progression (Table 1) .
Do all patients with RRMS ultimately progress?
Four models were applied to the population-based cohort using Kaplan-Meier estimates of time to progression and age at progression onset ( 
Does the presence (BOPMS) or absence (PPMS) of a pre-progression symptomatic relapsing-remitting phase impact age at progression onset?
Our hypothesis required comparison of SPMS and SAPMS with PPMS for age at progression onset. Studying the preprogression disease course in PPMS is akin to ascertaining all radiologically isolated syndrome (RIS) patients in the population [16] [17] [18] [19] and is not practical. Since about one-third of RRMS patients may also never develop progressive disease course it was more appropriate to exclude yet-to-progress RRMS patients for a head-to-head comparison of age at progression onset between BOPMS and PPMS.
Given the similar sex ratio, age at progression onset, and ratio of attainment of EDSS6 before progression between the two cohorts, patients with progressive MS from each cohort were combined. Distribution of age at first clinical symptoms of MS and age at progression onset stratified by disease course (PPMS, SAPMS, SPMS) revealed that age at MS onset was earlier for patients with SPMS (31.8 ± 9.3) versus SAPMS (37.4 ± 9.4) versus PPMS (45.7 ± 10.8) (p<0.001) ( Figure 4 ). However, age at progression onset did not differ by disease course (SPMS: 44.9 ± 9.6, SAPMS: 45.5 ± 9.6, PPMS: 45.7 ± 10.8, p=0.23). We also found that while the proportion of patients who experienced relapses after progression onset differed by disease course (SPMS 27.3%, SAPMS 12.3%, PPMS 0.3%; p<0.0001), age at last relapse after progression did not differ by disease course (SPMS 48.1±9.5, SAPMS 49.6±8.8, PPMS 47.8±10.2; p>0.05).
Discussion
We made several specific observations that pertain to the onset of progressive disease course in MS. About one-third of RRMS patients may never develop a progressive disease course. Age at progression onset is similar between BOPMS and PPMS. Age at progression onset is similar between a population-based cohort and a clinic-based cohort ascertained within the same clinical practice setting. Sustained moderate disability seems to be attained predominantly after the onset of a progressive disease course in MS. We discuss these findings individually below.
Switching from relapses to progression in MS is an age-dependent process independent of preprogression disease course or disease duration
We novelly show that almost all patients with MS develop a progressive disease course before age 75 (or by 35 years post-MS onset), while 38% of patients with RRMS are predicted not to develop progression by age 75. Identifying the intriguing underlying biology and predictors of nonprogression can help design novel therapeutics to prevent progression, improve patient counseling and help better stratify patients for clinical trials.
Age at progression onset was independent of pre-progression clinical relapse-based classification of PPMS, SAPMS or SPMS in the current study, as previously reported. 2, 5 We confirm that onset of progression in MS is age-rather than pre-progression disease duration-dependent. 7, 8 PPMS occurs only infrequently in children, 20, 21 further supporting that progression is an age-dependent process.
In the current study, ongoing relapses after progression onset were more common in SPMS than in SAPMS or PPMS, mirroring the frequency of pre-progression clinical relapses. However, a novel finding is that the age at last relapse was similar regardless of disease course classification of PPMS, SAPMS or SPMS. The end of the relapsing phase, like the onset of progressive phase in MS, also seems to be an age-rather than disease duration-dependent process.
Recent imaging studies suggest that myelination of the compact white matter ends by the fourth decade, followed by a slow degeneration in the white matter tracts in the following decades. 22, 23 Continued white matter tract repair (myelin and axons) may compensate for degeneration in previously damaged areas of the central nervous system until the end of fourth decade. An advancing degenerative phenotype afterwards is possibly reflected by the clinical progression surfacing in the fifth decade, as in our study.
The relapsing phase of MS can manifest as symptomatic relapses (i.e. RRMS) or subclinical lesions (i.e. RIS). [16] [17] [18] [19] -table analyses and mean (± standard deviation) values are shown for SPMS versus SAPMS versus PPMS. All patients with progressive MS from both cohorts are included in the analyses. In the population-based cohort from the Olmsted County, MN (n=210), we excluded patients with RRMS (n=109) and patients whose age at onset of progression was not clear (n=1 SAPMS). In the clinic-based referral patients (n=773), we excluded patients where presence or absence of pre-progression relapses were not well documented (n=19). Age at progression does not differ according to whether there were preceding relapses, but age at onset of MS, defined either by the first relapse (SPMS and SAPMS) or progression onset (PPMS), is significantly earlier for SPMS compared with SAPMS and compared with PPMS. 'Progression' refers to insidious and irreversible worsening brain, brainstem-cerebellar and spinal cord syndromes most commonly characterized by progressive weakness, ataxia or bladder dysfunction of ≥1 year.
The current diagnostic criteria for MS utilize subclinical lesions by magnetic resonance imaging (MRI) to establish dissemination in time and space during the first encounter with the patient who has already had a clinical relapse or has a slowly progressive disease course. 24 Patients with PPMS may have an 'established' lesion load on MRI at onset of progression indistinguishable from that in patients with SPMS. SPMS follows RRMS clinically, while PPMS follows RIS in a similar but subclinical continuum. 25, 26 In patients matched for the total number of brain and spinal cord lesions, SPMS and PPMS differ by the presence of previous and ongoing inflammatory demyelination and recovery potential of individual lesions, but share a similar spectrum of slowly expanding demyelination and axonal injury. 27 Our study further contributes to the unifying clinical scheme that SPMS, SAPMS and PPMS likely share a common neurodegenerative mechanism of progression but differ by the extent to which inflammatory-demyelinating activity manifests as preceding clinical relapse(s). 2, 5 
Recruitment of patients with progressive MS to studies through referral practices does not introduce any significant additional biases than expected in population-based cohorts that could impact age at progression onset determination
While population-based studies are the standard for studies like ours, we had a paucity of SAPMS and PPMS patients when compared with SPMS in our population-based cohort. Therefore we studied an additional clinic-based cohort established from our practice. The higher incidence of SAPMS (14%) and PPMS (41%) in the clinic-based cohort than in our population-based cohort (6% and 15%) and another population-based cohort 5 confirms that patients with less common forms of progressive MS than SPMS are over-represented among patients referred to tertiary care practices. Inclusion of the clinic-based cohort of patients could have potentially introduced additional recall and referral biases to our analyses. To address this we compared the two populations with each other. We found that when ascertainment and follow-up are conducted in a relatively uniform clinical practice setting, age at progression onset and attaining the disability milestone of EDSS6 in the retrospective tertiary clinic-based cohort were similar to that of the prospective population-based cohort. We noted that the age at progression onset was 1 year younger in the population-based cohort, a small difference that did not reach statistical significance within the power limitations of our study.
Age at MS onset in RRMS did not differ between those with and those without secondary progression in the population-based cohort, but was older in the clinic-based cohort compared with the population-based cohort. This suggested a potential recall bias for age at MS onset in the largely retrospective clinic-based cohort. However, our primary outcome measure of age at progression onset did not differ significantly between clinic-based and populationbased cohorts or between regional or non-regional referrals. Therefore, age at progression onset, a more recent and potentially more life-changing event than the first MS event, did not appear to be as prone to a potential recall bias as the age at MS onset.
Men are generally accepted to have older age at onset of MS and more severe disease than women 1,9 but men were only slightly over-represented in our clinic-based practice; this did not reach statistical significance within the power limitations of our study. However, it is possible that the nonsignificant 1-year delay in age at progression onset in the clinic-based cohort is due to a slightly higher representation of men in this population. Time to EDSS6 did not differ between clinic-based and the population-based cohorts of progressive MS, either. We confidently concluded that our results regarding age at progression onset were therefore unlikely to be confounded by a major recall or referral bias specific to the clinic-based cohort.
Commonly used disease-modifying medications (DMDs) in MS do not seem to impact progressive disease course after it is established, except for some benefit on preventing additional disability burden that may ensue because of superimposed relapses. 28 It is, however, unclear if DMDs can delay onset of progression in the first place in patients with BOPMS. Since our study is not planned as a prevention trial and PPMS patients naturally did not have preprogression DMD use, there was no way to properly control for this factor in our analyses when comparing age at progression onset between BOPMS and PPMS.
EDSS6 is a disability milestone that is reached predominantly after the onset of progressive disease course in MS
EDDS6 and higher levels of the scale are biased towards the longest corticospinal tracts and naturally could reflect the impact of progression-related disability. 5, 10 Progressive disease course has been the strongest determinant of sustained disability measured by EDSS. [1] [2] [3] [4] 9, [29] [30] [31] Attainment of the disability milestone of sustained EDSS4 is inevitably followed by further worsening of disability. 32 Disability progression can result from relapses that partially recover, or a progressive disease course, or both. The contribution of relapses on disability progression decreases in time. 33 Individual relapses affecting the efferent motor pathways are less likely than relapses affecting afferent pathways to lead to chronic impairment in patients with MS. 34 While almost all patients with SPMS develop the progressive phase of MS when their disability is EDSS6 or less, 5 it was not known what percentage of patients with RRMS without progression reach sustained EDSS6. A recent clinic-based study found that only 0.3% of individual relapses resulted in a sustained disability of EDSS6 or greater. 35 In our study, 2% of patients without progression reached sustained EDSS6, representing the population-based frequency of 'malignant relapsingremitting' cases of MS. 36 In contrast, regardless of the cohort, 98% of patients who developed progression reached EDSS6 after progression onset. We conclude that EDSS6 is a disability milestone that is reached predominantly after the onset of progressive disease course in MS.
Interestingly, as in the case for developing progressive disease course in MS, the speed of reaching the EDSS milestones seems to be age-rather than pre-progression disease course-dependent. 32, 37, 38 This intricate relationship between age of the patient, onset of progressive disease course and evolution of disability milestones needs to be accounted for in clinical trials and epidemiology studies in MS.
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